血液淋巴肿瘤免疫组化更新解读
本文综述了2022年WHO分类和国际共识分类更新后,血液淋巴肿瘤免疫组化标志物的新进展与新用途,旨在帮助病理医生应对小活检标本诊断挑战,并强调免疫组化在疾病诊断、分型及治疗管理中的持续扩展作用。
要点
- 2022年WHO分类与国际共识分类均更新了血液淋巴肿瘤的免疫组化标志物。
- 小活检标本评估淋巴结病持续挑战诊断,并增加免疫组化使用。
- 病理医生需掌握不断扩展的免疫组化标志物库以支持诊断与治疗。
核心结论
- 实践中的血液病理医生需要了解不断扩展的免疫组化标志物库,以用于血液淋巴肿瘤的诊断和治疗。
- 本文介绍的新标志物有助于完善对疾病、诊断和管理的理解。
研究设计与样本
- 本文为综述,数据来源于文献回顾和个人实践经验。
主要发现
- 2022年WHO分类发布了造血和淋巴组织肿瘤更新,随后另一组发布了髓系肿瘤、急性白血病和成熟淋巴瘤的国际共识分类。
- 无论选择遵循哪个系统,两个出版物及原始文献均描述了免疫组化诊断的更新。
- 小活检样本用于评估淋巴结病的增加持续挑战血液病理诊断并增加免疫组化使用。
临床怎么用
- 血液病理医生应了解2022年WHO分类和国际共识分类中免疫组化标志物的更新。
- 在小活检标本评估淋巴结病时,应考虑免疫组化标志物的新用途以辅助诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: In their 2014 article "New Immunohistochemistry for B-cell Lymphoma and Hodgkin Lymphoma," Zhang and Aguilera reviewed new immunohistochemical markers for B-cell lymphoma and Hodgkin lymphoma and described how to use these markers for correct lymphoma diagnoses, using the 2008 World Health Organization classifications. Recently, the World Health Organization's WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues published 2022 updates, and, in quick sequence, a second group published an alternative International Consensus Classification of myeloid neoplasms, acute leukemias, and mature lymphoid neoplasms. Regardless of the system a hematopathologist chooses to follow, updates in the immunohistochemical diagnosis of disease are described in both publications as well as in the primary literature. In addition to updated classifications, the increasing use of small biopsy samples for the evaluation of lymphadenopathy continues to challenge hematopathology diagnosis and increase the utilization of immunohistochemistry. OBJECTIVE.—: To review new immunohistochemical markers or new uses of previously known immunohistochemical markers in the evaluation of hematolymphoid neoplasia for the practicing hematopathologist. DATA SOURCES.—: Data were obtained from a literature review and personal practice experience. CONCLUSIONS.—: The practicing hematopathologist requires knowledge of the ever-expanding repertoire of immunohistochemistry for the diagnosis and treatment of hematolymphoid neoplasia. New markers presented in this article help to complete our understanding of disease, diagnosis, and management.
引用
- Kavus H, Ding Y, Dhesi M, et al. Updates in Immunohistochemistry for Hematopoietic and Lymphoid Neoplasms. Arch Pathol Lab Med. 2024. PMID: 37270801. doi:10.5858/arpa.2022-0465-RA
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。